Philippe Drouet joined Biotheryx as President and CEO in October 2021. Prior, he served as Chief Commercial Officer at CRISPR Therapeutics, where he shaped the strategy for the launch of the Company’s first allogeneic CAR-T therapies and helped lead the clinical development strategy for the Company’s Phase I clinical assets. Previously, Philippe served as Senior Vice President, Global Oncology at Merck & Co., where he launched and commercialized Keytruda®, drove substantial global oncology revenue and built and led the Company’s Global Oncology Marketing, Access and Pricing organization. Previously, he served as President of Hospira’s U.S. division before Hospira’s acquisition by Pfizer in 2015. Philippe also held roles of increasing responsibility at Novartis Pharmaceutical Corporation, including Vice President U.S. Hematology, General Manager Oncology in Turkey, Global Brand Leader for Gleevec® and Head of Oncology Marketing in Canada. Philippe received an M.S. and B.S. in Chemical Engineering from McGill University in Canada and an M.B.A. from INSEAD in France.